for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

InVitae Corp

NVTA.N

Latest Trade

30.95USD

Change

1.19(+4.00%)

Volume

466,706

Today's Range

29.79

 - 

31.58

52 Week Range

7.42

 - 

35.30

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
29.76
Open
29.91
Volume
466,706
3M AVG Volume
64.87
Today's High
31.58
Today's Low
29.79
52 Week High
35.30
52 Week Low
7.42
Shares Out (MIL)
131.79
Market Cap (MIL)
3,921.93
Forward P/E
-10.85
Dividend (Yield %)
--

Next Event

Invitae Corp Annual Shareholders Meeting

Latest Developments

More

Invitae And Archerdx To Create A Global Leader In Comprehensive Cancer Genetics And Precision Oncology

Invitae Says Q1 Preliminary Non-GAAP Loss Per Share Of $0.80

Invitae Says Selling Stockholders May Sell Up To Aggregate Of 808,145 Shares Of Co's Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

Industry

Computer Services

Contact Info

1400 16th St

SAN FRANCISCO, CA

94103-5110

United States

+1.415.3747782

https://www.invitae.com

Executive Leadership

Sean E. George

Chairman of the Board, President, Chief Executive Officer, Co-Founder

Shelly D. Guyer

Chief Financial Officer

Kenneth Knight

Chief Operating Officer

Robert F. Werner

Chief Accounting Officer

Thomas R. Brida

General Counsel, Secretary

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019

0.2K

2020(E)

0.3K
EPS (USD)

2017

-2.650

2018

-1.940

2019

-2.280

2020(E)

-3.435
Price To Earnings (TTM)
--
Price To Sales (TTM)
16.82
Price To Book (MRQ)
8.42
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
59.88
LT Debt To Equity (MRQ)
59.67
Return on Investment (TTM)
-64.41
Return on Equity (TTM)
-57.11

Latest News

Latest News

BRIEF-Invitae And Archerdx To Create A Global Leader In Comprehensive Cancer Genetics And Precision Oncology

* INVITAE AND ARCHERDX TO CREATE A GLOBAL LEADER IN COMPREHENSIVE CANCER GENETICS AND PRECISION ONCOLOGY

BRIEF-Invitae Says Q1 Preliminary Non-GAAP Loss Per Share Of $0.80

* INVITAE REPORTS MORE THAN $64 MILLION IN REVENUE DRIVEN BY MORE THAN 154,000 SAMPLES ACCESSIONED IN THE FIRST QUARTER OF 2020

BRIEF-Invitae Says Selling Stockholders May Sell Up To Aggregate Of 808,145 Shares Of Co's Common Stock

* INVITAE CORP SAYS SELLING STOCKHOLDERS MAY SELL UP TO AGGREGATE OF 808,145 SHARES OF CO'S COMMON STOCK -SEC FILING Source text: [https://bit.ly/2KjZD11] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Invitae Says Selling Stockholders May Sell Up To Aggregate Of 1.8 Mln Shares Of Common Stock

* INVITAE CORP - SELLING STOCKHOLDERS MAY SELL UP TO AGGREGATE OF 1.8 MILLION SHARES OF COMMON STOCK - SEC FILING Source text: [https://bit.ly/2wZ9t5m] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Axovant Announces Partnership With Invitae To Increase Access To Genetic Testing And Accelerate Diagnoses Of Gm1 And Gm2 Gangliosidosis

* AXOVANT ANNOUNCES PARTNERSHIP WITH INVITAE TO INCREASE ACCESS TO GENETIC TESTING AND ACCELERATE DIAGNOSES OF GM1 AND GM2 GANGLIOSIDOSIS

BRIEF-Invitae Announces Pricing Of Public Offering Of Common Stock

* INVITAE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Invitae Corp Withdrawing Its Revenue, Test Volume And Cash Burn Guidance For 2020

* INVITAE CORP - WITHDRAWING ITS REVENUE, TEST VOLUME AND CASH BURN GUIDANCE FOR 2020

BRIEF-Invitae Announces Proposed Public Offering Of Common Stock

* INVITAE CORP - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $125.0 MILLION OF SHARES OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Invitae Acquires Diploid, Maker Of AI Engine To Enable Clinical Diagnosis Using Whole Genome Sequencing In Minutes

* INVITAE ACQUIRES DIPLOID, MAKER OF ARTIFICIAL-INTELLIGENCE ENGINE TO ENABLE CLINICAL DIAGNOSIS USING WHOLE GENOME SEQUENCING IN MINUTES

BRIEF-Invitae To Acquire Youscript And Genelex

* INVITAE TO ACQUIRE YOUSCRIPT AND GENELEX TO MAKE IT EASIER TO USE PHARMACOGENETIC INFORMATION AT THE POINT OF CARE

BRIEF-Invitae Corp Reports Q4 Loss Per Share $0.79

* INVITAE REPORTS $216.8 MILLION IN ANNUAL REVENUE DRIVEN BY MORE THAN 482,000 SAMPLES IN 2019

BRIEF-Invitae Reports Q1 Loss Per Share $0.66

* INVITAE REPORTS 169% REVENUE GROWTH DRIVEN BY 150% GROWTH IN VOLUME IN FIRST QUARTER 2018

BRIEF-Invitae Announces Pricing Of Public Offering Of Common Stock

* INVITAE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Invitae Announces Proposed Public Offering Of Common Stock

* INVITAE CORP - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF SHARES OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Invitae Corp - Co And Its Units Borrowed An Additional Term Loan In An Aggregate Amount Of $20 Million ​

* INVITAE CORP - ON MARCH 12, 2018, CO AND ITS UNITS BORROWED AN ADDITIONAL TERM LOAN IN AN AGGREGATE AMOUNT OF $20 MILLION - SEC FILING Source text (http://bit.ly/2p8gFVl) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Invitae Corp Reaches Agreement With Oxford Finance To Expand Existing Loan And Security Agreement

* INVITAE EXPANDS EXISTING CREDIT FACILITY TO PROVIDE UP TO $40.0 MILLION IN AVAILABLE GROWTH CAPITAL

BRIEF-Invitae reports Q4 Loss Per Share $0.78

* INVITAE REPORTS OVER 150% VOLUME AND OVER 170% REVENUE GROWTH FOR 2017

BRIEF-Invitae Reports Q4 Loss Per Share $0.78

* INVITAE REPORTS OVER 150% VOLUME AND OVER 170% REVENUE GROWTH FOR 2017

BRIEF-Invitae More Than Doubles Annual Volume, Exceeds Full-Year 2017 Guidance, Projects Momentum To Continue In 2018

* INVITAE MORE THAN DOUBLES ANNUAL VOLUME, EXCEEDS FULL-YEAR 2017 GUIDANCE, AND PROJECTS MOMENTUM TO CONTINUE IN 2018

BRIEF-Park West Asset Management LLC Reports 5 Pct Passive Stake In Invitae Corp As Of Nov 21

* PARK WEST ASSET MANAGEMENT LLC REPORTS 5.0 PERCENT PASSIVE STAKE IN INVITAE CORP AS OF NOVEMBER 21, 2017 - SEC FILING Source text: [http://bit.ly/2AAc70V] Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up